The Bronx, NY Clinical Trials Report — June 2026

For residents of The Bronx, NY, June 2026 presents a dynamic landscape of clinical trial opportunities, with some studies nearing their enrollment deadlines and exciting new research initiatives beginning. Timely action is key for those interested in participating, especially for trials closing soon.

A total of 38 clinical trials in The Bronx are scheduled to conclude within the next 90 days. Among these, 9 trials are still actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition before these opportunities close.

Urgent Opportunities for Participation

Patients managing specific health conditions also have limited time to join certain research studies. Trials focused on various conditions are among those with impending deadlines for enrollment. Conditions with trials closing soon include:

• Tricuspid regurgitation (2 trials)
• Solid tumor (2 trials)
• Solid tumor, adult (2 trials)
• Suicide (2 trials)
• Subarachnoid hemorrhage (2 trials)
• Solid tumor, unspecified, adult (2 trials)
• Intracerebral hemorrhage (2 trials)
• Cervical carcinoma (1 trial)
• Breast cancer (1 trial)
• Atrial fibrillation (1 trial)

New Research Initiatives in The Bronx

This month, The Bronx saw the launch of 10 new clinical trials, a notable increase from the 5 trials that opened in May 2026. This brings the total number of actively recruiting clinical trials in The Bronx to 558 across 195 research facilities, highlighting the city's active role in medical research.

June's new trials include several significant Phase 3 studies from major sponsors, offering participants access to cutting-edge treatments and diagnostic approaches across various health challenges:

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics is sponsoring NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)." This Phase 3, randomized, double-blind, placebo-controlled study plans for 1,100 participants to evaluate the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in individuals living with overweight or obesity and Type 2 Diabetes Mellitus (T2DM).
• AstraZeneca is initiating NCT07662135, "A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin." This Phase 3 study aims for 900 participants to assess elecoglipron's efficacy and safety in adults with T2DM and impaired renal function who are already on dapagliflozin.
• Montefiore Medical Center is sponsoring NCT07625267, "Non-antibiotic Management in Acute Uncomplicated Diverticulitis." This Phase 4 study seeks 556 participants to explore non-antibiotic treatments for mild diverticulitis, a common condition causing swelling and pain in the large intestine.
• Also from Montefiore Medical Center, NCT07625917, "Feasibility of Internet-based HIV Prevention Research," aims for 500 participants. This study will use social media to recruit people who self-report injecting drugs, assessing the feasibility of online assessments and at-home self-administered HIV testing.
• The HIV Prevention Trials Network is leading NCT07658976, "Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy." This Phase 3b trial targets 400 participants to evaluate an integrated strategy of HIV pre-exposure prophylaxis (PrEP) and sexually transmitted infection (STI) post-exposure prophylaxis (PEP) for young men.
• Eli Lilly and Company is sponsoring NCT07668336, "A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes." This Phase 3 study involves 170 pediatric participants aged 10 to less than 18 years with Type 2 Diabetes, comparing the efficacy and safety of orforglipron to dulaglutide.

New trials this month are addressing a variety of conditions, including acute uncomplicated diverticulitis, adenoidectomy, cesarean scar defect (isthmocele), chronic weight management, Type 2 diabetes mellitus, HIV-1 infection, HIV infection, HIV prevention, injection drug use, and metabolic syndrome. The majority of new studies are DRUG trials (7), with others including BEHAVIORAL (1), DEVICE (1), DIAGNOSTIC_TEST (1), and PROCEDURE (1) trials.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are opportunities to contribute to research. Of the 10 new trials launched this month, 2 are actively seeking healthy volunteers. Across The Bronx, a total of 45 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Leading Research Facilities in The Bronx

The Bronx is home to several prominent research institutions that consistently conduct a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Montefiore Medical Center (159 trials)
• Montefiore Medical Center - Moses Campus (76 trials)
• Montefiore Medical Center-Einstein Campus (60 trials)
• Montefiore Medical Center-Weiler Hospital (28 trials)
• Research Site (19 trials)
• Albert Einstein College of Medicine (16 trials)
• Children's Hospital at Montefiore (16 trials)
• James J. Peters VA Medical Center, Bronx, NY (13 trials)
• Jacobi Medical Center (12 trials)
• Montefiore Einstein Comprehensive Cancer Center (12 trials)

These institutions offer a broad spectrum of research, with Montefiore Medical Center and its various campuses leading the way in trial volume, alongside Albert Einstein College of Medicine and the James J. Peters VA Medical Center.

Broadening Your Search: Nearby Options

While The Bronx offers a substantial number of clinical trial opportunities, individuals may also find options in other communities within New York State. Nearby cities with active trials include New York (62 trials), Commack (12 trials), Harrison (9 trials), Rochester (9 trials), Uniondale (6 trials), Albany (5 trials), Brooklyn (5 trials), and Manhasset (4 trials).

Participation in clinical trials is open to a diverse range of individuals. Of the 10 new trials launched this month, 7 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 2 new trials include children, 2 are female-only, and 1 is male-only. Academic institutions, particularly Montefiore Medical Center (4 trials), continue to play a vital role in The Bronx's research ecosystem. Industry sponsors like Eli Lilly and Company, Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, and AstraZeneca are also driving significant research efforts.

As we move through June, The Bronx's active research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.